Jiande Cheng
Research Subjects
Research Interests
Jiande Cheng has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Cheng Qian
Center for Precision Medicine of Cancer, Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital and Chongqing University School of Medicine, Chongqing, China
1 shared publication - Huijing Feng
Shanxi Bethune Hospital 2
1 shared publication - Jia Wei
Department of Hematology, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, China
1 shared publication - Jiaqi Guo
Department of Hematology Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital Taiyuan China
1 shared publication - Jie Zhao
Shanxi Bethune Hospital 2
1 shared publication - Jingyi Liu
Shanxi Bethune Hospital 2
1 shared publication
Latest Publications
- Open Access
- 27 October 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
Hypoxia-inducible CEA-targeted CAR T-cell therapy for relapsed stage IV non-small cell lung cancer
Mitigating on-target off-tumor toxicity remains a central challenge for chimeric antigen receptor (CAR) T-cell therapy for solid tumors. We developed a hypoxia-inducible CAR-T-cell product targeting carcinoembryonic antigen (CEA) that restricts CAR activation to hypoxic tumor niches via oxygen-dependent expression control. In this first-in-human, phase I trial enrolling heavily pretreated patients with relapsed stage IV non-small cell lung cancer (NSCLC), a single infusion of the investigational product achieved an objective response rate of 47% and a disease control rate of 87%, with a manageable safety profile. Exploratory analyses showed that clinical outcomes were associated with baseline factors. Deep single-cell profiling indicated that the clinical response was associated with the expansion of hypoxia-adapted, tumor-reactive-like CD8+ T cells alongside coordinated functional maturation of natural killer (NK) cells. Collectively, these data provide clinical proof-of-concept for hypoxia-inducible CAR design and inform the rational development of strategies leveraging tumor microenvironmental features in solid tumor cellular immunotherapy.
- 27 October 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
Open AccessHypoxia-inducible CEA-targeted CAR T-cell therapy for relapsed stage IV non-small cell lung cancer
Mitigating on-target off-tumor toxicity remains a central challenge for chimeric antigen receptor (CAR) T-cell therapy for solid tumors. We developed a hypoxia-inducible CAR-T-cell product targeting carcinoembryonic antigen (CEA) that restricts CAR activation to hypoxic tumor niches via oxygen-dependent expression control. In this first-in-human, phase I trial enrolling heavily pretreated patients with relapsed stage IV non-small cell lung cancer (NSCLC), a single infusion of the investigational product achieved an objective response rate of 47% and a disease control rate of 87%, with a manageable safety profile. Exploratory analyses showed that clinical outcomes were associated with baseline factors. Deep single-cell profiling indicated that the clinical response was associated with the expansion of hypoxia-adapted, tumor-reactive-like CD8+ T cells alongside coordinated functional maturation of natural killer (NK) cells. Collectively, these data provide clinical proof-of-concept for hypoxia-inducible CAR design and inform the rational development of strategies leveraging tumor microenvironmental features in solid tumor cellular immunotherapy.
- Open Access
- 29 December 2025
- Published by Springer Nature in Journal of Biological Engineering
- Vol. 19 (1) , 111
Combined drugs-loaded nano-lipodisk carrier for pH-responsive delivery for improved therapeutic potential on lung cancer model
Recently, combination therapy has gotten more attention for some progressive therapeutic cancers. In in vivo studies, combination therapy requires better d
- 29 December 2025
- Published by Springer Nature in Journal of Biological Engineering
- Vol. 19 (1) , 111
Open AccessCombined drugs-loaded nano-lipodisk carrier for pH-responsive delivery for improved therapeutic potential on lung cancer model
Recently, combination therapy has gotten more attention for some progressive therapeutic cancers. In in vivo studies, combination therapy requires better d